These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35819571)

  • 1. ASO Author Reflections: Inheritance of Adrenal Permissive HSD3B1 Genotype Negatively Impacts Outcomes in Hormone Receptor-Positive Postmenopausal Breast Cancer.
    Flanagan MR; Sharifi N; Gadi VK
    Ann Surg Oncol; 2022 Oct; 29(11):7202-7203. PubMed ID: 35819571
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.
    Flanagan MR; Doody DR; Voutsinas J; Wu Q; Banda K; Sharifi N; Li CI; Gadi VK
    Ann Surg Oncol; 2022 Oct; 29(11):7194-7201. PubMed ID: 35776258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.
    Kruse ML; Patel M; McManus J; Chung YM; Li X; Wei W; Bazeley PS; Nakamura F; Hardaway A; Downs E; Chandarlapaty S; Thomas M; Moore HC; Budd GT; Tang WHW; Hazen SL; Bernstein A; Nik-Zainal S; Abraham J; Sharifi N
    JCI Insight; 2021 Oct; 6(20):. PubMed ID: 34520399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer.
    McManus JM; Vargas R; Bazeley PS; Schumacher FR; Sharifi N
    JNCI Cancer Spectr; 2022 Sep; 6(5):. PubMed ID: 35947687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
    Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
    JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.
    Chang YC; Chen CK; Chen MJ; Lin JC; Lin CH; Huang WC; Cheng SP; Chen SN; Liu CL
    Ann Surg Oncol; 2017 Dec; 24(13):4033-4041. PubMed ID: 28744792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2- Breast Cancer?
    Amlicke MJ; Spanheimer PM
    Ann Surg Oncol; 2022 Nov; 29(12):7670-7671. PubMed ID: 35831528
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.
    Shiota M; Fujimoto N; Sekino Y; Tsukahara S; Nagakawa S; Takamatsu D; Abe T; Kinoshita F; Ueda S; Ushijima M; Matsumoto T; Kashiwagi E; Inokuchi J; Uchiumi T; Oda Y; Eto M
    Andrologia; 2022 Feb; 54(1):e14307. PubMed ID: 34747051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality.
    Schiffer L; Sharifi N
    JAMA Netw Open; 2024 Mar; 7(3):e243402. PubMed ID: 38506812
    [No Abstract]   [Full Text] [Related]  

  • 10. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
    Hettel D; Sharifi N
    Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.
    Chang YC; Lin CH; Lin JC; Cheng SP; Chen SN; Liu CL
    J Surg Res; 2019 Sep; 241():8-14. PubMed ID: 31004874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
    Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
    Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors.
    Wasserman L; Flatt SW; Natarajan L; Laughlin G; Matusalem M; Faerber S; Rock CL; Barrett-Connor E; Pierce JP
    Int J Obes Relat Metab Disord; 2004 Jan; 28(1):49-56. PubMed ID: 14557830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
    Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
    Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.
    Andersen SW; Trentham-Dietz A; Figueroa JD; Titus LJ; Cai Q; Long J; Hampton JM; Egan KM; Newcomb PA
    Menopause; 2013 Mar; 20(3):354-8. PubMed ID: 23435034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
    Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of the genetic variant within miRNA-binding site in estrogen receptor alpha gene on the risk of breast cancer in postmenopausal women on hormone replacement therapy.
    Cerne JZ; Gersak K; Novakovic S
    Cancer Biomark; 2010-2011; 8(3):123-8. PubMed ID: 22012767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.